Mend Lands $15M Series A Financing Round
NEW YORK, NY, Mend, a life sciences and digital health company operating at the intersection of nutrapharma, food as medicine, and behavioral health, has received a round of Series A funding.
The $15 million round is led by S2G Ventures, a leading multi-stage investment firm dedicated to backing innovative, market-based solutions to advance a more humane and healthy planet.
Other investors included iSelect Fund, Touchdown Ventures, Colorcon Ventures, Keen Growth Capital, Genhen Capital, Alumni Ventures and others.
Mend is a life sciences company that is passionate about bringing the power of healing to people everywhere. Operating at the intersection of nutrapharma and digital wellness, mend helps and enables people who want to repair, recover, and return to life faster and better. The mend nutrapharma products are clinically proven, science backed, and recognized by the medical community to be effective in accelerating repair, recovery, and improving key risk factors contributing to chronic conditions. Integrated with one-on-one coaching powered by AI, the mend platform pushes the paradigm on digital wellness. Driven to improve societal health and bridge the gap between human health and human nature, mend works with leading hospitals and universities on developing evidence-based programs to enhance patient outcomes. Mend is the worlds' first whole-person, nutrapharma powered platform used by elite soldiers, athletes, and professional teams, and is endorsed by many of the country's most respected doctors, surgeons, and health systems.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
(c) by Massinvestor, Inc. For contact info, please check out our about